FDA

Are Food Regulators Stepping up to the Plate?

Are Food Regulators Stepping up to the Plate?

In this week’s Saturday Seminar, we collect scholarship discussing quality and safety issues within U.S. food regulation.

Using Insurance to Regulate Food Safety

Using Insurance to Regulate Food Safety

Insurance underwriters can help farmers manage the risk of microbial contamination in their fields.

Cancer Moonshot Lands with FDA

Cancer Moonshot Lands with FDA

FDA releases new guidelines for cancer clinical trials in response to President Biden’s anti-cancer initiative.

With Proposed Menthol Cigarette Rule, FDA Says Cool It

With Proposed Menthol Cigarette Rule, FDA Says Cool It

FDA issues proposed rule that would ban menthol as a flavor additive in cigarettes.

Making Regulations on Influencer Advertising Click

Making Regulations on Influencer Advertising Click

Scholars offer approaches to improve regulation of social media marketing.

Emergency Use or Overuse?

Emergency Use or Overuse?

Experts discuss FDA’s COVID-19 emergency authorizations and how to recalibrate the regulatory mechanism.

Preparing the New Market for Meat Alternatives

Preparing the New Market for Meat Alternatives

As the alternative meat industry takes off, regulation will confront a new frontier.

The Future of Feces

The Future of Feces

As fecal microbiota transplantation gains traction in the medical world, regulators may need to step in.

Sniffing Out New Regulation

Sniffing Out New Regulation

Scholars propose to modify the current regulatory regime for animal-based medical diagnostics.

Hidden Racial Disparities in FDA-Required Research

Hidden Racial Disparities in FDA-Required Research

Current testing practices in the pharmaceutical industry exploit social and racial inequities.

The (Un)Regulation of Tattoo Ink

The (Un)Regulation of Tattoo Ink

FDA should increase its regulatory oversight of tattoo ink safety.

CMS Confronts an Increase in Medicare Part B Premiums

CMS Confronts an Increase in Medicare Part B Premiums

CMS reconsiders a recent Medicare premium increase after restricting coverage for a controversial new drug.